Notably, there have been documented cases of GBS following stem cell transplantation in patients receiving tacrolimus for graft-versus-host disease (GVHD) prophylaxis, in patients undergoing treatment with immune checkpoint inhibitors, and even in patients after anti-B-cell maturation antigen (BCMA) chimeric antigen receptor T-cell (CAR-T) therapy [2,3]. Here, TNFRSF17 is linked to graft versus host disease.